Navigation Links
Post-Chemo Treatment May Boost Lung Cancer Survival
Date:5/20/2010

Study finds some benefit with erlotinib for people with non-small-cell form of disease

THURSDAY, May 20 (HealthDay News) -- Among people with non-small-cell lung cancer, treatment with the drug erlotinib (Tarceva) after chemotherapy appears to slightly boost survival rates, a new study suggests.

Non-small-cell lung cancer makes up about 85 percent of lung cancer cases. About half the time, people have advanced disease when diagnosed and are treated solely with chemotherapy, usually platinum-based chemo. But chemotherapy only boosts survival by eight to 10 months, the study authors noted.

The study findings, which support the use of erlotinib as a "maintenance" treatment, are based on research by Dr. Federico Cappuzzo of the Civil Hospital of Livorno in Italy and his colleagues. The researchers tested the drug in 889 people who'd had chemotherapy and whose disease had not gotten worse. They were randomly assigned to take erlotinib an inactive placebo.

According to the study, published online May 19 in The Lancet Oncology, the drug improved overall survival, compared with the placebo (12 months versus 11 months). The length of time without the disease progressing also was somewhat better for those who took the drug: 12 rather than 11 weeks. Most people tolerated the drug well, with skin rash and diarrhea being the most common side effect, the study found, but serious side effects affected 11 percent of those who took the drug, compared with 8 percent of those taking the placebo.

"The acceptable tolerability profile of erlotinib, together with proven efficacy in all patient subgroups and oral dosing, distinguishes erlotinib from other agents in this setting and could provide greater treatment choice for clinicians," the researchers concluded.

More information

The American Cancer Society has details about non-small-cell lung cancer.



-- Randy Dotinga



SOURCE: The Lancet Oncology, news release, May 19, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Book Delivers Latest ADHD Research, Treatments & Results
2. Early Treatment With Clot-Busting Drug Best After Stroke
3. CIGNA and Cancer Treatment Centers of America Reach New Agreement
4. New hope for better treatment for a rising cancer
5. Passages to Recovery Outdoor Addiction Treatment Program Achieves Joint Commission Accreditation
6. New technology aids in prostate cancer treatment
7. Impotence Drugs May Aid Brain Tumor Treatment
8. Self-directed behavioral IBS treatment rapidly relieves even the most severe symptoms
9. Researchers discover new way to rescue treatment sensitivity of breast cancer cells
10. Smarter use of existing treatment helps dramatically boost survival of young AML patients
11. Med Spa Treatments Become More Popular as Unemployment Rates Climb
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... 27, 2017 , ... Plastic Surgery Associates is excited to announce that Heather ... the upcoming Aesthetic Meeting. Held in San Diego, at the San Diego Convention Center, ... lend their expertise to the Premier Global Hot Topics session, speaking on genital rejuvenation. ...
(Date:4/26/2017)... ... April 26, 2017 , ... The ... Awards recipients, comprised of organizations and individuals who have stretched the boundaries ... 2017 President’s Awards recognize individuals and organizations on the forefront of healthcare ...
(Date:4/26/2017)... ... April 26, 2017 , ... The National Business ... National Registry of Emergency Medical Technicians and welcomes this organization to ... Dr. Jan G. West, Ph.D. , CEO & Organizational Psychologist at NBRI. “This ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want ... unique website ( CRISPRCas.pioneer.com ) that demonstrates how this advanced plant breeding technology ... and better food, with fewer resources. It highlights the business’ principles, research and ...
(Date:4/25/2017)... ... ... Bellus Medical, a leader in medical aesthetics, recently acquired ... photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically formulated to ... minimize the appearance of pores – all with minimal downtime and results that ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... and Gynecology markets with innovative and proprietary products, will ... 31, 2017 after the market close on Tuesday, May ... a conference call and webcast to discuss its financial ... at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
(Date:4/18/2017)...  Astute Medical, Inc., developer of biomarkers for better ... at the 2017 National Kidney Foundation (NKF) Spring ... April 22. Physicians will present data on two biomarkers, ... for acute kidney injury (AKI) during the management of ... Elevated levels of TIMP-2 and IGFBP-7 have been ...
Breaking Medicine Technology: